謝幸

擅長(zhǎng)： 腫瘤診斷與治療。

簡(jiǎn)介： [簡(jiǎn) 歷] 1983年畢業(yè)于浙江大學(xué)醫(yī)學(xué)院(原浙江醫(yī)科大學(xué))，曾赴德國(guó)、美國(guó)等國(guó)留學(xué)。從事婦產(chǎn)科臨床、教學(xué)及科研工作三十余年，以婦科腫瘤為主要研究方向。是浙江省有突出貢獻(xiàn)中青年專家，澳大利亞西澳大學(xué)“Raine杰出訪問(wèn)教授”。曾獲浙江省優(yōu)秀教師、浙江大學(xué)首屆教學(xué)名師獎(jiǎng)、“浙江省優(yōu)秀院長(zhǎng)”等稱號(hào)。主持或參加國(guó)家、省部級(jí)科研項(xiàng)目數(shù)50余項(xiàng);曾獲國(guó)家科技進(jìn)步獎(jiǎng)二等獎(jiǎng)2項(xiàng)，中華醫(yī)學(xué)獎(jiǎng)一等獎(jiǎng)和教育部科學(xué)技術(shù)獎(jiǎng)一等獎(jiǎng)、二等獎(jiǎng)各1項(xiàng);國(guó)家發(fā)明專利2項(xiàng)。發(fā)表學(xué)術(shù)論著300余篇，其中SCI源期刊論文100余篇。 現(xiàn)任國(guó)家重點(diǎn)(培育)學(xué)科和浙江省重點(diǎn)學(xué)科-婦產(chǎn)科學(xué)學(xué)科帶頭人，國(guó)家臨床重點(diǎn)?？?婦科學(xué)科帶頭人，浙江省女性生殖健康研究重點(diǎn)實(shí)驗(yàn)室主任，浙江省宮頸疾病診治中心主任，國(guó)家級(jí)精品課程負(fù)責(zé)人。是中華醫(yī)學(xué)會(huì)婦產(chǎn)科學(xué)分會(huì)副主任委員，中華醫(yī)學(xué)會(huì)婦科腫瘤學(xué)分會(huì)副主任委員，浙江省醫(yī)學(xué)會(huì)婦產(chǎn)科學(xué)分會(huì)主任委員，浙江省抗癌協(xié)會(huì)婦科腫瘤專業(yè)委員會(huì)主任委員等。擔(dān)任人民衛(wèi)生出版社國(guó)家規(guī)劃教材《婦產(chǎn)科學(xué)》專升本教材(第一、第二版)主編、5年制教材(第八版)主編、長(zhǎng)學(xué)制教材編者，是中華醫(yī)學(xué)雜志英文版、中華醫(yī)學(xué)雜志、中華婦產(chǎn)科雜志等10余種雜志的編委。 近年發(fā)表的SCI文獻(xiàn)： (1)Interleukin-7 and Suppression of Local Peritoneal Immunity in Ovarian Carcinoma. Int J Gynecol Obstet 2004;85:151-158. (通訊作者) (2)Effect of Interleukin-7 Gene Transfection into Ovarian Carcinoma Cell Line SKOV3 In vitro and In vivo. Gynocol Oncol 2004;92(2)：578-585. (通訊作者) (3)Ovarian cacinoma cells inhibit T cell proliferation: suppression of IL-12 receptor β and γ expression and their JAK-STAT signaling. Life Science 2004;74(14): 1739-1749. (通訊作者) (4)VEGF And Ovarian Cancer Cell Supernatant Activate Signal Transducers And Activators Of Transcription (STATs) Via VEGF Receptor-2 (KDR) In Human Hemopoietic Progenitor Cells. Gynocol Oncol 2004;94:125-133(通訊作者) (5)VEGF,VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol,2004;94:630-635(通訊作者) (6)Impaired mixed lymphocyte reaction in intrahepatic cholestasis of pregnancy. Gynecol Obstet Invest,2002:54:191-195 (7)Sedentary behaviours and epithelial ovarian cancer risk. Cancer Causes and Control,2004;15:83-89 (8)The value of curettage in diagnosis of endometrial hyperplasia. Gynecol Oncol. 2002;84(1):135-139. (通訊作者) (9)Lack of mutation in tumor-suppressor gene p53 in gestational trophoblastic tumours. Br J Cancer 1996;73:1216-1219. (10)Cell culture of biopsied endometriomas after danazol/hormonal therapy:A study of growth features and fertility effects. Indian J Exper Bio.2000;38:1192-1200. (11)Ovarian Carcinoma Cells Effectively Inhibit Differentiation And Maturation Of Dendritic Cells Derived From Hematopoietic Progenitor Cells In Vitro. Cancer Investigation, in printing. (通訊作者) (12) Mismatch repair gene promoter methylation and expression in hydatidiform moles. Arch Gynecol Obstet. 2005;272:35-39; (通訊作者) (13) PTEN Promoter Methylation and Protein Expression in Normal Early Placentas and Hydatidiform Moles. J Soc Gynecol Investig 2005;12:214 –7 (14) Proportion of CD4+CD25+ regulatory T cell is increased in the paitients with ovarian cancer. Cancer Investigation. 2005, in printing. (通訊作者) (15)Growth inhibition of interleukin-2 receptor gene-tranduced peripheral blood lymphocytes on human ovarian cancer cells. Chin Med J, 2001; 114 (3): 303-307. [主攻學(xué)科] 婦產(chǎn)科 [研究方向] 卵巢癌與腹腔免疫缺陷及其機(jī)制，宮頸癌發(fā)生的免疫學(xué)和分子遺傳學(xué)機(jī)制，妊娠滋養(yǎng)細(xì)胞疾病發(fā)病的分子遺傳學(xué)機(jī)制